Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

387
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
387
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

150
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
150
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

127
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
127
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

201
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
201
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

228
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same author

Antimicrobial use trends in Canadian adult hematology/oncology inpatient wards: a multi-year exploratory analysis from 2018 to 2023.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Unmet targets: evaluating vancomycin use and predictive factors of target attainment in hemodialysis patients.

Expert review of anti-infective therapy·2026
Same author

A simulation study to assess the influence of population pharmacokinetic model selection on Bayesian forecasting of vancomycin exposure in preterm neonates.

Expert review of clinical pharmacology·2026
Same author

β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses.

Clinical pharmacokinetics·2026

Related Experiment Video

Updated: Sep 13, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.0K

Population Pharmacokinetic Model Evaluation with a Small Real-World Dataset Versus a Large Virtual Dataset: Does

Mehdi El Hassani1,2, Daniel J G Thirion3,4, Amélie Marsot3,5

  • 1Faculté de pharmacie, Université de Montréal, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada. mehdi.el.hassani@umontreal.ca.

European Journal of Drug Metabolism and Pharmacokinetics
|July 29, 2025
PubMed
Summary

Small clinical datasets can effectively evaluate population pharmacokinetic (PK) models, confirming previous simulation findings. This validation using real-world data supports efficient model development in drug research.

Keywords:
ModelingPiperacillinSimulation

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.6K

Related Experiment Videos

Last Updated: Sep 13, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.0K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.6K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Clinical Pharmacology
  • Drug Development

Background:

  • Previous simulation studies indicated minimal impact of sample size on external population pharmacokinetic (PK) model evaluation.
  • The applicability of these findings to real-world clinical data required validation.

Purpose of the Study:

  • To validate simulation-based findings using actual clinical data.
  • To assess the external evaluation of population PK models with small clinical datasets.

Main Methods:

  • Collected clinical data from elderly patients receiving piperacillin/tazobactam.
  • Simulated a virtual population of 1000 patients.
  • Externally evaluated a population PK model using both clinical and simulated datasets.
  • Assessed model performance using bias, imprecision, goodness-of-fit plots, and prediction-corrected visual predictive checks.

Main Results:

  • External evaluation of a population PK model was performed on a small clinical dataset (13 patients) and a simulated dataset.
  • No significant differences were observed in prediction error distributions between the clinical and simulated datasets.
  • Goodness-of-fit plots and visual predictive checks indicated similar model misspecification for both datasets.

Conclusions:

  • Small clinical datasets are adequate for the external evaluation of population PK models.
  • Findings support the use of limited clinical data in PK model assessment.